PrimeraDx Appoints Jeff Liter as VP of Corporate Development

MANSFIELD, Mass., Oct. 13, 2011 /PRNewswire/ -- PrimeraDx today announced that Jeff Liter has been appointed as the Vice President of Corporate Development.  

"Jeff's diverse background in all aspects of corporate development makes him a great addition to the leadership team," Said Matt McManus, President and CEO, PrimeraDx.  "PrimeraDx's strategy is to leverage the multimodal capabilities of the ICEPlex system in the MDx market and define a model for the next generation of molecular diagnostics.  Jeff has a great deal of experience that will help bring scale to our commercial efforts."

Mr. Liter has more than 20 years of experience in business development, sales, corporate finance and operations.  Prior to joining PrimeraDx, he was the Director of Strategy, Business Development, & Licensing for Beckman Coulter, where he was responsible for Business Development of the Immunoassay and Molecular Diagnostics Groups.  Jeff also was the managing director with On Point Consulting, focusing on Post Acquisition Integration Support and Transactional Advisory Services.  Specifically, he delivered integration services to Onyx Pharmaceuticals and established a Knowledge Transfer Program within the first 3 months of a critical integration.  He received his MBA from University of Minnesota and his BA from Illinois State University.

"The ICEPlex platform is already creating a stir in the MDx community, with the ability to assay mRNAs, microRNAs and SNPs in the same well, from a single sample," Commented Mr. Liter.  "I am excited to work with Matt and the team, to develop the company's customer base and strategic alliances."

About PrimeraDx

PrimeraDx is dedicated to the high growth field of molecular diagnostics.  The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system.  PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, [email protected]

SOURCE PrimeraDx